Centessa Pharmaceuticals (CNTA) Revenue & Revenue Breakdown
Centessa Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$6.88M
Main Segment (Y)
Lixivaptan
Main Geography (Y)
Lixivaptan
Centessa Pharmaceuticals Revenue by Period
Centessa Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $6.88M | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Centessa Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $6.91M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | - |
Centessa Pharmaceuticals Revenue Breakdown
Centessa Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 21 |
---|---|
Lixivaptan | $200.00M |
Latest
Centessa Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 21 |
---|---|
Lixivaptan | $200.00M |
Latest
Centessa Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
STRO | Sutro Biopharma | $153.73M | $25.71M |
TRDA | Entrada Therapeutics | $129.01M | $19.57M |
GNFT | Genfit | $28.57M | $17.08M |
TARS | Tarsus Pharmaceuticals | $17.45M | $48.12M |
CNTA | Centessa Pharmaceuticals | $6.88M | - |
CRNX | Crinetics Pharmaceuticals | $4.01M | - |
IPSC | Century Therapeutics | $2.23M | $791.00K |
OPT | Opthea | $108.41K | $61.27K |
DSGN | Design Therapeutics | - | - |
CGEM | Cullinan Oncology | - | - |
CCCC | C4 Therapeutics | - | - |
NUVL | Nuvalent | - | - |
IRON | Disc Medicine | - | - |
ERAS | Erasca | - | - |
MLYS | Mineralys Therapeutics | - | - |
LRMR | Larimar Therapeutics | - | - |
HLVX | HilleVax | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
EWTX | Edgewise Therapeutics | - | - |
CNTA Revenue FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools